These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8904183)

  • 1. Dosing and monitoring NovoSeven treatment.
    Hedner U
    Haemostasis; 1996; 26 Suppl 1():102-8. PubMed ID: 8904183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
    Hoffman M; Monroe DM
    Dis Mon; 2003 Jan; 49(1):14-21. PubMed ID: 12525825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.
    Qi X; Zhao Y; Li K; Fan L; Hua B
    Blood Coagul Fibrinolysis; 2014 Oct; 25(7):754-60. PubMed ID: 24806320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
    Hoffman M; Monroe DM
    Semin Hematol; 2001 Oct; 38(4 Suppl 12):6-9. PubMed ID: 11735103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis.
    Hedner U; Ezban M
    Annu Rev Med; 2008; 59():29-41. PubMed ID: 17845136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First 20 years with recombinant FVIIa (NovoSeven).
    Hedner U; Lee CA
    Haemophilia; 2011 Jan; 17(1):e172-82. PubMed ID: 20609014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombelastgram as a hemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII.
    Yoshioka A; Nishio K; Shima M
    Haemostasis; 1996; 26 Suppl 1():139-42. PubMed ID: 8904189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of tissue factor and factor VIIa in hemostasis.
    Mackman N
    Anesth Analg; 2009 May; 108(5):1447-52. PubMed ID: 19372318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful use of recombinant FVIIa (Novoseven) in the management of uncontrolled bleeding after emergency fasciotomy.
    Sipahi T; Kuybulu A
    Haemophilia; 2008 Sep; 14(5):1145-6. PubMed ID: 18624703
    [No Abstract]   [Full Text] [Related]  

  • 10. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.
    Valentino LA; Cooper DL; Goldstein B
    Haemophilia; 2011 Jul; 17(4):579-89. PubMed ID: 21294815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of FVII:C and FVIIa assays for the monitoring of recombinant factor VIIa treatment.
    Cid AR; Lorenzo JI; Haya S; Montoro JM; Casaña P; Aznar JA
    Haemophilia; 2001 Jan; 7(1):39-41. PubMed ID: 11136379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged in-vivo half-life of factor VIIa by fusion to albumin.
    Weimer T; Wormsbächer W; Kronthaler U; Lang W; Liebing U; Schulte S
    Thromb Haemost; 2008 Apr; 99(4):659-67. PubMed ID: 18392323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NovoSeven (recombinant factor VIIa) in centeral nervous systems bleeds.
    Rice KM; Savidge GF
    Haemostasis; 1996; 26 Suppl 1():131-4. PubMed ID: 8904187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future pharmacological strategies in management of Haemophilia.
    Sørensen B
    Thromb Res; 2010 Oct; 126(4):259-61. PubMed ID: 20153023
    [No Abstract]   [Full Text] [Related]  

  • 15. Recombinant coagulation factor VIIa--from molecular to clinical aspects of a versatile haemostatic agent.
    Persson E; Bolt G; Steenstrup TD; Ezban M
    Thromb Res; 2010 Jun; 125(6):483-9. PubMed ID: 20006996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FVIIa as therapeutic agent in hemophilia and beyond.
    Hedner U
    Front Biosci (Elite Ed); 2012 Jan; 4(4):1210-23. PubMed ID: 22201947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the factor VII:C clot analysis and a modified activated factor VII analysis for monitoring factor VII activity in patients treated with recombinant activated factor VII (NovoSeven).
    Johannessen M; Nielsen G; Nordfang O
    Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S159-64. PubMed ID: 10850583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of action of factor VIIa in the treatment of coagulopathies.
    Hedner U
    Semin Thromb Hemost; 2006 Apr; 32 Suppl 1():77-85. PubMed ID: 16673269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
    Goldstein B; Geldziler B; Bjerre J; Seremetis S
    Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NovoSeven for non-hemophilia hemostasis.
    Med Lett Drugs Ther; 2004 Apr; 46(1181):33-4. PubMed ID: 15114252
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.